276687-49-1

Basic information

• Product Name: 3-AMINO-2-PHENOXYMETHYL-3 H-QUINAZOLIN-4-ONE
• Synonyms: 3-AMINO-2-PHENOXYMETHYL-3 H-QUINAZOLIN-4-ONE;AKOS AU36-M16;AKOS B028849
• CAS NO: 276687-49-1
• Molecular Formula: C₁₅H₁₃N₃O₂
• Molecular Weight: 267.28
• Mol File: 276687-49-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 479.5±47.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• PKA: -1.65±0.20(Predicted)
• CAS DataBase Reference: 3-AMINO-2-PHENOXYMETHYL-3 H-QUINAZOLIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-2-PHENOXYMETHYL-3 H-QUINAZOLIN-4-ONE(276687-49-1)
• EPA Substance Registry System: 3-AMINO-2-PHENOXYMETHYL-3 H-QUINAZOLIN-4-ONE(276687-49-1)

Safety Data

• Hazardous Substances Data: 276687-49-1(Hazardous Substances Data)

Upstream product

• 701-99-5 Phenoxyacetyl chloride 
• 101284-14-4 methyl 2-(2-phenoxyacetamido)benzoate 
• 1026638-84-5 N-(2-hydrazinocarbonyl-phenyl)-2-phenoxy-acetamide 
• 134-20-3 2-carbomethoxyaniline 
• 108-95-2 phenol 
• 122-59-8 2-phenoxyacetic acid 

Downstream Products

• 371141-04-7 3-chloro-N-(4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-yl)propanamide 
• 1150095-01-4 2-chloro-N-(4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-yl)acetamide 
• 1150095-11-6 3-((4-(2-chlorophenyl)piperazin-1-yl)methylamino)-2-(phenoxymethyl)quinazolin-4(3H)-one 

Relevant articles and documents

Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma

Inhibiting Cyclin-dependent kinase 2 (CDK2) has been established as a therapeutic strategy for the treatment of many cancers. Accordingly, this study aimed at developing a new set of quinazolinone-based derivatives as CDK2 inhibitors. The new compounds were evaluated for their anticancer activity against sixty tumour cell lines. Compounds 5c and 8a showed excellent growth inhibition against the melanoma cell line MDA-MB-435 with GI% of 94.53 and 94.15, respectively. Cell cycle analysis showed that compound 5c led to cell cycle cessation at S phase and G2/M phase revealing that CDK2 could be the plausible biological target. Thus, the most cytotoxic candidates 5c and 8a were evaluated in?vitro for their CDK2 inhibitory activity and were able to display significant inhibitory action. The molecular docking study confirmed the obtained results. ADME study predicted that 5c had appropriate drug-likeness properties. These findings highlight a rationale for further development and optimisation of novel CDK2 inhibitors.

Design, synthesis and antihistaminic (H1) activity of some condensed 3- aminopyrimidin-4(3H)-ones

A novel series of condensed 3-amino-2-(substituted)methylpyrimidin- 4(3H)-ones is reported with potential H1 receptor antagonistic activity. The IC50 values for 23 compounds were found to be in the micromolar range. Five lead compounds (10c, e, g, r and t), when evaluated by the in vivo method were found to protect guinea-pigs from the histamine induced asphyxia and antagonized histamine in a competitive and reversible manner. With a pA2 value of 8.7 and protection time of 9.5 min (in vivo test), compound 10g was the most active amongst these five compounds. The isosteric replacement of the side chain -NH- in series 1, by oxygen and -NHSO2- functions, was undertaken to investigate the role of two amino functions in the receptor binding. This isosteric replacement with -O- does not affect the antihistaminic activity and the sedative potential of the series. Preliminary molecular modelling, studies indicate that the compounds with -NHSO2- in the side chain exhibit a closer fit with temelastine than their -O- isosteres. (C) 2000 Editions scientifiques et medicales Elsevier SAS.